Pressure BioSciences Inc (OTCMKTS:PBIO) announced that it’s targeting the third quarter to release its new BaroShear Mini device, a bench-top CBD oil-processing instrument utilizing the company’s Ultra Shear Technology (UST).
The Baroshear Mini works by taking extracted CBD oil — notoriously difficult for the water-based human body to absorb — and processes it so that it’s dissolvable in water. That significantly increases the amount of CBD that enters circulation, a metric known as bioavailability.
The incredibly small droplets created by UST nanoemulsions are able to exceed the dosing efficiencies of today’s CBD oil, the company said.
READ: Pressure BioSciences shares rocket on CBD-oil processing systems purchase order from Las Vegas cannabis CEO
"It has become apparent that Pressure BioSciences' breakthrough UST platform is a potential market-changing technology enabling a new generation of CBD and other cannabinoid products to more effectively meet consumer and supplier objectives,” CEO Richard Schumacher said in a statement. “By delivering effective water solubility of cannabinoids, PBI's UST offers the promise of high absorption rates and bioavailability from ingestion or topical application of cannabinoid products.”
The BaroShear Mini is the company’s third device within the BaroShear product family, offering a smaller, more compact way to get the same nanoemulsions expected from UST.
“The aggressive marketing campaign we have underway for the pre-sale of our BaroShear K45 system and for the 2021 release of our industrial-scale BaroShear Max instrument has been well received by manufacturing laboratories,” director of UST, Kenneth Micciche said. “However, it has become apparent that product research and development labs prefer a smaller, bench-top, lower price-point, minimal throughput UST-based instrument. The BaroShear Mini clearly answers that need and will do so without cannibalizing sales to larger manufacturing facilities."
The South Easton, Massachusetts-based company is confident the new iteration will spur revenue growth in 2020.
"We believe that PBI will transform a vast range of applications with UST, that extend across multiple very large markets from dairy and other foods/beverages to pharmaceuticals, nutraceuticals, and industrial applications,” chairman Jeffrey Peterson said. “This is the technology platform that we believe will propel PBI into multi-billion dollar market opportunities, with resulting market value realization for our shareholders."
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel